Advertisement

---

Health Business news
2018-01-03
NeuroVive to Present at the 10th Annual Biotech Showcase Conference

NeuroVive to Present at the 10th Annual Biotech Showcase Conference



LUND, Sweden, Jan. 3, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced that the company is scheduled to present the 10th Annual Biotech Showcase Conference, held 8-10 January 2018 in San Francisco, USA.

The presentation will highlight the company's project portfolio, primarily the clinical programs for traumatic brain injury (TBI) with the NeuroSTAT project, currently in phase II clinical development, and genetic mitochondrial disease with the KL1333 project, currently in phase I clinical development. The presentation will also cover developments in the company's preclinical programs, particularly the NASH projects for out-licensing, NV556 and NVP022.

The presentation will take place on 8 January 2018, at 4:00 p.m. PST (9 January at 1:00 a.m. CET). Audio and slide presentation will be made available on NeuroVive's web site at http://www.neurovive.com/investor/company-presentations.

Date: Monday, 8 January 2018Time: 4:00 p.m. PSTTrack: Franciscan - A (Ballroom Level)

For more information please contact:

Daniel SchaleDirector of Communications+46(0)46-275-62-21ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)

Medicon VillageSE-223 81 LundSwedenTel: +46(0)46-275-62-20 (switchboard)info@neurovive.comwww.neurovive.com

About NeuroVive 

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company's strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/neurovive-pharmaceutical/r/neurovive-to-present-at-the-10th-annual-biotech-showcase-conference,c2424581

The following files are available for download:

http://mb.cision.com/Main/6574/2424581/773389.pdf PDF

View original content:http://www.prnewswire.com/news-releases/neurovive-to-present-at-the-10th-annual-biotech-showcase-conference-300576848.html
SOURCE NeuroVive Pharmaceutical




Prev Article
Next Article

> Article Date par NeuroVive Pharmaceutical

Read: 2 views

Notes :

Source : PR Newswire

Advertisement

Related content

: Latest news

Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers